What you should know:
– Sanofi, a global biopharmaceutical company focused on human health, has signed a strategic partnership with which BrightInsight, Inc., provider of the leading global platform for regulated biopharmaceutical and technology regulated digital healthcare solution to bring to market a next-generation complementary digital application for one of Sanofi’s products.
– The BrightInsight® platform has been selected to serve as the underlying infrastructure to accelerate the continued development of one of Sanofi’s best medical device programs.
Next generation Digital Companion application
Leveraging the BrightInsight® platform, Sanofi’s accompanying digital application will provide easy access to patient services and support patients from the incorporation of therapy to the management of chronic diseases with the aim of improving experiences and health outcomes of patients. The solution consists of a mobile application for patients, which integrates with third-party systems to create a connected ecosystem, and will allow users to manage their complex conditions with a personalized profile and content, and a user guide. step-by-step therapy administration. The application will be available first in the US and then launched in international markets.
“BrightInsight has a history of partnering with innovative, forward-looking biopharmaceutical leaders such as Sanofi, who understand the value created by regulated digital health solutions that support treatment,” said Kal Patel, MD, CEO and co-founder of BrightInsight. “Our deep experience in launching software as a medical device, regulatory experience and a solid platform allow us to support Sanofi’s goals of accelerating time to market and deliver an exceptional patient experience in a way that comply with the various critical, complex quality, privacy and security regulations.